Eligibility focused on p16-negative/HPV-unrelated, PD-L1 ≥1% recurrent/metastatic HNSCC recurring ≥6 months after curative-intent platinum, reflecting a high ...
Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous cell cancer (HNSCC), an expert has said. This follows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results